Citi raised the firm’s price target on BioAge Labs (BIOA) to $52 from $15 and keeps a Buy rating on the shares. The firm sees a “compelling” outlook for the shares as BioAge approaches proof-of-concept data for BGE-102. Citi sees blockbuster potential for BGE-102 across both indications with peak U.S. sales of $9.5B in atherosclerotic cardiovascular disease and $2B in diabetic macular edema.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on BIOA:
- BioAge Labs: Differentiated NLRP3 Inhibitor BGE-102 Positions Company for Best-in-Class Cardiometabolic Upside and Strategic M&A Appeal
- BioAge Labs initiated with an Outperform at Oppenheimer
- Midday Fly By: Berkshire cuts Amazon stake, MSG Sports weighs spinoff
- BioAge Labs upgraded to Buy from Hold at Jefferies
- BioAge Labs price target raised to $23 from $12 at Morgan Stanley